In these alternative solutions, recombinant albumin not only has the advantage of being able to be mass-produced at a lower cost, but also avoids the risk of transmission of blood diseases (Bah et al., 2018; Heroes et al., 2020). The gene discussed is ALB; the disease is blood disease.